hotspot -WSS

hotspot

author：explore 2025-09-29 21:02:19 - browse：11127

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Archived: an online chat discussing Ebola, vaccines, and a new epidemic

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

The wait for US passports is creating travel purgatory and snarling summer plans

UpToDate has a racism problem: Dr. Stanley Goldfarb

What to expect at HLTH 2023, the health care industry conference

What affirmative action's end means to a medical student

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

Analysis of telehealth claims data suggest service duplication

How one medical school became remarkably diverse

Crowdfunding for unproven stem cell procedures spreads misinformation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Stroke deaths set to near 10 million globally by 2050

Bright Health sells Medicare Advantage business to Molina

Drug cartel violence flares in western Mexico after vigilante leader's killing

Medical leaders decry Supreme Court decision on affirmative action

Phenylephrine and the overlooked value of the placebo effect

Wikipedia

Lupron, used to halt puberty in children, may cause lasting health problems

Drug cartel violence flares in western Mexico after vigilante leader's killing

Canadians with cystic fibrosis outlive Americans by a decade

Was Amgen transparent enough on FDA's concern on cancer drug?

Prescription digital therapeutics are key to pharma’s future

Analysis of telehealth claims data suggest service duplication

focus

focus

leisure time

Wikipedia